Details of Drug

Drug General Information (ID: D0244)
Drug Name	Calcium Phosphate
Drug Type	Small molecule
Drug Synonymous	Calcium phosphate; 7758-87-4; TRICALCIUM PHOSPHATE; Synthos; Calcium phosphate tribasic; Calcium orthophosphate; Tricalcium diphosphate; Calcigenol simple; beta-TCP; Phosphoric acid, calcium salt (2:3); Tricalcium orthophosphate; beta-Tricalcium phosphate; Calcium tertiary phosphate; Tertiary calcium phosphate; tri-calcium phosphate; tricalcium;diphosphate; FEMA No. 3081; 10103-46-5; Calciresorb;TCP; Phosphoric acid, calcium salt; UNII-K4C08XP666; tricalcium bis(phosphate); CHEBI:9679; K4C08XP666; Synthograft; Bonarka; Cerasorb; OSferion; Natural whitlockite; Caswell No. 148; Ceredex; Multifos; Ostram; Vitoss; TricOs; Calipharm T; Tricafos P; Calcium phosphate (3:2); 21063-37-6; Tricalcium bis(orthophosphate); CCRIS 3668; HSDB 879; JAX TCP; Calcium phosphate (Ca3(PO4)2); Calcium orthophosphate, tri-(tert); Tricalcium phosphate (Ca3(PO4)2); EINECS 231-840-8; EPA Pesticide Chemical Code 076401; Posture (calcium supplement); bone phosphate; Phosphoric acid calcium(2+) salt (2:3); Ca3(PO4)2; Bone ash; calcium-phosphate; alpha-TCP; Calcium phosphates; tricalciumphosphate; EINECS 233-283-6; Posture (TN); Hydroxyapatite Powder; MFCD00015984; Phosphoric acid, calcium salt (1:?); calcium phosphate basic; beta tricalcium phosphate; AI3-25607; alpha-Tricalcium phosphate; Ca3O8P2; EC 231-840-8; BONE POWDER, PURIFIED; INS NO.341(III); INS-341(III); CHEMBL2106566; DTXSID1049803; E-341(III); AKOS015833108; CX-0072; DB11348; S338; Tricalcium bis(orthophosphate), with a fluorine content of less than 0,005 % by weight on the dry anhydrous product; Calcium phosphate, tribasic (ca.37% Ca); CS-0013475; FT-0645103; C08136; D00938; Q278387; UNII-97Z1WI3NDX component QORWJWZARLRLPR-UHFFFAOYSA-H; UNII-279O8I0433 component QORWJWZARLRLPR-UHFFFAOYSA-H; Calcium phosphate, Reagent for transient & stable DNA transfections; beta-tri-Calcium phosphate, >=95% beta-phase basis (unsintered powder); Calcium phosphate, purum p.a., >=96.0% (calc. as Ca3(PO4)2, KT); Tricalcium phosphate hydrate, nanopowder, <200 nm particle size (BET); alpha-tri-Calcium phosphate, puriss. p.a., >=75% alpha-phase basis (sinterted powder); alpha-tri-Calcium phosphate, Reagent for transient & stable DNA transfections; beta-tri-Calcium phosphate, puriss. p.a., >=95% beta-phase basis (sintered powder); beta-tri-Calcium phosphate, puriss. p.a., >=98% beta-phase basis (sintered Powder); beta-tri-Calcium phosphate, puriss. p.a., >=98% beta-phase basis (unsintered powder) Click to Show/Hide
Therapeutic Class	Minerals And Electrolytes/Phosphate Binders
Structure
Structure	3D Structure		2D Structure
Formula	Ca3O8P2
InChI	InChI=1S/3Ca.2H3O4P/c;;;21-5(2,3)4/h;;;2(H3,1,2,3,4)/q3*+2;;/p-6
InChIKey	QORWJWZARLRLPR-UHFFFAOYSA-H
Canonical SMILES	[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2]
External Link
	Pubchem ID	24456
	VARIDT ID	DR00339

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM003 Affected organization distribution AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM003 Complex formation BM014 Interference of cell/tissue uptake BM089 Antagonize the effect of antihypertensive agents BM107 Attenuated pharmacological effects (Unspecific) BM108 Increased risk of hypercalcemia BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Calcium Phosphate
Affected gastrointestinal absorption
	Complex formation					Drug Num: 36
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0181		Bictegravir	C21H18F3N3O5	90311989	Major		Inter Info	[1], [2], [3]
D0515		Dolutegravir	C20H19F2N3O5	54726191	Major		Inter Info	[6], [7]
D0034		Alendronic acid	C4H13NO7P2	2088	Moderate		Inter Info	[8], [9], [10]
D0144		Baloxavir marboxil	C27H23F2N3O7S	124081896	Moderate		Inter Info	[1], [19]
D0438		Delafloxacin	C18H12ClF3N4O4	487101	Moderate		Inter Info	[20], [21], [22]
D1175		Omadacycline	C29H40N4O7	54697325	Moderate		Inter Info	[23], [24], [25]
D1445		Sarecycline	C24H29N3O8	54681908	Moderate		Inter Info	[23], [24], [25]
D0340		Cinoxacin	C12H10N2O5	2762	Moderate		Inter Info	[20], [21], [22]
D0341		Ciprofloxacin	C17H18FN3O3	2764	Moderate		Inter Info	[20], [21], [22]
D0433		Deferiprone	C7H9NO2	2972	Moderate		Inter Info	[26]
D0441		Demeclocycline	C21H21ClN2O8	54680690	Moderate		Inter Info	[23], [24], [25]
D0530		Doxycycline	C22H24N2O8	54671203	Moderate		Inter Info	[23], [24], [25]
D0561		Eltrombopag	C25H22N4O4	135449332	Moderate		Inter Info	[2], [30]
D0573		Enoxacin	C15H17FN4O3	3229	Moderate		Inter Info	[20], [21], [22]
D0623		Etidronic acid	C2H8O7P2	3305	Moderate		Inter Info	[9], [31], [10]
D0712		Gatifloxacin	C19H22FN3O4	5379	Moderate		Inter Info	[20], [21], [22]
D0716		Gemifloxacin	C18H20FN5O4	9571107	Moderate		Inter Info	[20], [21], [22]
D0740		Grepafloxacin	C19H22FN3O3	72474	Moderate		Inter Info	[20], [21], [22]
D0783		Ibandronate	C9H23NO7P2	60852	Moderate		Inter Info	[8], [9], [10]
D0919		Levofloxacin	C18H20FN3O4	149096	Moderate		Inter Info	[20], [21], [22]
D0925		Levothyroxine	C15H11I4NO4	5819	Moderate		Inter Info	[32], [33], [34]
D0934		Liothyronine	C15H12I3NO4	5920	Moderate		Inter Info	[32], [33], [34]
D0935		Liotrix	C30H21I7N2Na2O8	71371	Moderate		Inter Info	[32], [33], [34]
D0943		Lomefloxacin	C17H19F2N3O3	3948	Moderate		Inter Info	[20], [21], [22]
D1070		Minocycline	C23H27N3O7	54675783	Moderate		Inter Info	[23], [24], [25]
D1102		Nalidixic acid	C12H12N2O3	4421	Moderate		Inter Info	[35]
D1165		Ofloxacin	C18H20FN3O4	4583	Moderate		Inter Info	[20], [21], [22]
D1209		Oxytetracycline	C22H24N2O9	54675779	Moderate		Inter Info	[23], [24], [25]
D1245		Penicillamine	C5H11NO2S	5852	Moderate		Inter Info	[36], [37], [38]
D1412		Risedronic acid	C7H11NO7P2	5245	Moderate		Inter Info	[8], [9], [10]
D1499		Sparfloxacin	C19H22F2N4O3	60464	Moderate		Inter Info	[20], [21], [22]
D1564		Tetracycline	C22H24N2O8	54675776	Moderate		Inter Info	[23], [24], [25]
D1577		Thyroid, porcine	NA	NA	Moderate		Inter Info	[32], [33], [34]
D1584		Tiludronic acid	C7H9ClO6P2S	60937	Moderate		Inter Info	[9], [31], [10]
D1635		Triethylenetetramine	C6H18N4	5565	Moderate		Inter Info	[40]
D1657		Trovafloxacin	C20H15F3N4O3	62959	Moderate		Inter Info	[20], [21], [22]
Affected organization distribution
	Interference of cell/tissue uptake					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1509		Strontium chloride Sr-89	Cl2Sr	5388879	Moderate		Inter Info	[1], [27], [39]
Pharmacodynamic additive effects
	Increased risk of hypercalcemia					Drug Num: 12
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0158		Bendroflumethiazide	C15H14F3N3O4S2	2315	Moderate		Inter Info	[14], [15], [16]
D0166		Benzthiazide	C15H14ClN3O4S3	2343	Moderate		Inter Info	[14], [15], [16]
D1753		Calcipotriol (topical)	C27H40O3	5288783	Moderate		Inter Info	[17], [18]
D1754		Calcitriol (topical)	C27H44O3	5280453	Moderate		Inter Info	[17], [18]
D0321		Chlorothiazide	C7H6ClN3O4S2	2720	Moderate		Inter Info	[14], [15], [16]
D0326		Chlorthalidone	C14H11ClN2O4S	2732	Moderate		Inter Info	[14], [15], [16]
D0771		Hydrochlorothiazide	C7H8ClN3O4S2	3639	Moderate		Inter Info	[14], [15], [16]
D0775		Hydroflumethiazide	C8H8F3N3O4S2	3647	Moderate		Inter Info	[14], [15], [16]
D0798		Indapamide	C16H16ClN3O3S	3702	Moderate		Inter Info	[14], [15], [16]
D1048		Metolazone	C16H16ClN3O3S	4170	Moderate		Inter Info	[14], [15], [16]
D1311		Polythiazide	C11H13ClF3N3O4S3	4870	Moderate		Inter Info	[14], [15], [16]
D1633		Trichlormethiazide	C8H8Cl3N3O4S2	5560	Moderate		Inter Info	[14], [15], [16]
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0221		Burosumab	NA	NA	Major		Inter Info	[4]
D0490		Digitoxin	C41H64O13	441207	Moderate		Inter Info	[27], [28], [29]
D0491		Digoxin	C41H64O14	2724385	Moderate		Inter Info	[27], [28], [29]
Pharmacodynamic antagonistic effects
	Antagonize the effect of antihypertensive agents					Drug Num: 10
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0069		Amlodipine	C20H25ClN2O5	2162	Moderate		Inter Info	[11], [12], [13]
D0170		Bepridil	C24H34N2O	2351	Moderate		Inter Info	[11], [12], [13]
D0640		Felodipine	C18H19Cl2NO4	3333	Moderate		Inter Info	[11], [12], [13]
D0865		Isradipine	C19H21N3O5	3784	Moderate		Inter Info	[11], [12], [13]
D0911		Levamlodipine	C20H25ClN2O5	9822750	Moderate		Inter Info	[11], [12], [13]
D1130		Nicardipine	C26H29N3O6	4474	Moderate		Inter Info	[11], [12], [13]
D1134		Nifedipine	C17H18N2O6	4485	Moderate		Inter Info	[11], [12], [13]
D1138		Nimodipine	C21H26N2O7	4497	Moderate		Inter Info	[11], [12], [13]
D1141		Nisoldipine	C20H24N2O6	4499	Moderate		Inter Info	[11], [12], [13]
D1690		Verapamil	C27H38N2O4	2520	Moderate		Inter Info	[11], [12], [13]
	Attenuated pharmacological effects (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0590		Erdafitinib	C25H30N6O2	67462786	Major		Inter Info	[5]

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir). Gilead Sciences, Foster City, CA.
4	Product Information. Crysvita (burosumab). Ultragenyx Pharmaceutical, Novato, CA.
5	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
6	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
7	Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
8	Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC.
9	Product Information. Boniva (ibandronate). Roche Laboratories, Nutley, NJ.
10	Product Information. Skelid (tilundronate). Sanofi Winthrop Pharmaceuticals, New York, NY.
11	Woie L, Storstein L "Successful treatment of suicidal verapamil poisoning with calcium gluconate." Eur Heart J 2 (1981): 239-42
12	Oszko MA, Klutman NE "Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension." Clin Pharm 6 (1987): 448-9
13	Lipman J, Jardine I, Roos C, Dreosti L "Intravenous calcium chloride as an antidote to verapamil-induced hypotension." Intensive Care Med 8 (1982): 55-7
14	Santos F, Smith MJ, Chan JC "Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide." Am J Dis Child 140 (1986): 139-42
15	Drinka PJ, Nolten WE "Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics." J Am Geriatr Soc 32 (1984): 405-7
16	Duarte CG, Winnacker JL, Becker KL, Pace A "Thiazide-induced hypercalcemia." N Engl J Med 284 (1971): 828-30
17	Product Information. Vectical (calcitriol topical). Galderma Laboratories Inc, Cranbury, NJ.
18	Product Information. Dovonex (calcipotriene). Westwood Squibb Pharmaceutical Corporation, Eatontown, NJ.
19	Product Information. Xofluza (baloxavir marboxil). Genentech, South San Francisco, CA.
20	Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
21	Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9. [PMID: 3382110]
22	Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7. [PMID: 9222077]
23	Gotz VP, Ryerson GG "Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease." Drug Intell Clin Pharm 20 (1986): 694-6. [PMID: 3757782]
24	Nguyen VX, Nix DE, Gillikin S, Schentag JJ "Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline." Antimicrob Agents Chemother 33 (1989): 434-6. [PMID: 2729939]
25	Upton RA "Pharmacokinetic interactions between theophylline and other medication (Part I)." Clin Pharmacokinet 20 (1991): 66-80. [PMID: 1674242]
26	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
27	Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8. [PMID: 88737]
28	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA."
29	Product Information. PhosLo (calcium acetate) Braintree, Braintree, MA.
30	Product Information. Promacta (eltrombopag). GlaxoSmithKline, Research Triangle Park, NC.
31	Product Information. Fosamax (alendronate). Merck &amp Co, Inc, West Point, PA.
32	Csako G, McGriff NJ, Rotman-Pikielny P, Sarlis NJ, Pucino F "Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders." Ann Pharmacother 35 (2001): 1578-83. [PMID: 11793625]
33	Neafsey PJ "Levothyroxine and calcium interaction: timing is everything." Home Healthc Nurse 22 (2004): 338-9. [PMID: 15131426]
34	Singh N, Singh PN, Hershman JM "Effect of calcium carbonate on the absorption of levothyroxine." JAMA 283 (2000): 2822-5. [PMID: 10838651]
35	Product Information. NegGram (nalidixic acid). Sanofi Winthrop Pharmaceuticals, New York, NY.
36	Lyle WH "Penicillamine and iron." Lancet 2 (1976): 420. [PMID: 73880]
37	Netter P, Bannwarth B, Pere P, Nicolas A "Clinical pharmacokinetics of D-penicillamine." Clin Pharmacokinet 13 (1987): 317-33. [PMID: 3319347]
38	Product Information. Cuprimine (penicillamine). Merck &amp Co, Inc, West Point, PA.
39	Multum Information Services, Inc. Expert Review Panel.
40	Product Information. Syprine (trientine). Aton Pharma, Lawrenceville, NJ.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence